675 related articles for article (PubMed ID: 20130567)
1. Trends in risks associated with new drug development: success rates for investigational drugs.
DiMasi JA; Feldman L; Seckler A; Wilson A
Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical R&D performance by firm size: approval success rates and economic returns.
DiMasi JA
Am J Ther; 2014; 21(1):26-34. PubMed ID: 23344103
[TBL] [Abstract][Full Text] [Related]
3. Clinical approval success rates for investigational cancer drugs.
DiMasi JA; Reichert JM; Feldman L; Malins A
Clin Pharmacol Ther; 2013 Sep; 94(3):329-35. PubMed ID: 23739536
[TBL] [Abstract][Full Text] [Related]
4. Spending on new drug development1.
Adams CP; Brantner VV
Health Econ; 2010 Feb; 19(2):130-41. PubMed ID: 19247981
[TBL] [Abstract][Full Text] [Related]
5. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
6. The value of drug repositioning in the current pharmaceutical market.
Tobinick EL
Drug News Perspect; 2009 Mar; 22(2):119-25. PubMed ID: 19330170
[TBL] [Abstract][Full Text] [Related]
7. The price of innovation: new estimates of drug development costs.
DiMasi JA; Hansen RW; Grabowski HG
J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
[TBL] [Abstract][Full Text] [Related]
8. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
9. [The discovery process in the pharmaceutical industry].
Scatton B
J Soc Biol; 2009; 203(3):249-69. PubMed ID: 19833071
[TBL] [Abstract][Full Text] [Related]
10. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
[TBL] [Abstract][Full Text] [Related]
11. Expanded access to investigational drugs for treatment use. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
[TBL] [Abstract][Full Text] [Related]
12. Drug development: from concept to marketing!
Tamimi NA; Ellis P
Nephron Clin Pract; 2009; 113(3):c125-31. PubMed ID: 19729922
[TBL] [Abstract][Full Text] [Related]
13. Can open-source drug R&D repower pharmaceutical innovation?
Munos B
Clin Pharmacol Ther; 2010 May; 87(5):534-6. PubMed ID: 20407458
[TBL] [Abstract][Full Text] [Related]
14. Novelty in the target landscape of the pharmaceutical industry.
Agarwal P; Sanseau P; Cardon LR
Nat Rev Drug Discov; 2013 Aug; 12(8):575-6. PubMed ID: 23903214
[No Abstract] [Full Text] [Related]
15. Discontinued drugs in 2008: oncology drugs.
Williams R
Expert Opin Investig Drugs; 2009 Nov; 18(11):1581-94. PubMed ID: 19663760
[TBL] [Abstract][Full Text] [Related]
16. Investigational drug tracking: Phases I-III and NDA submissions--Part I.
Grant KL
Hosp Pharm; 1994 Sep; 29(9):830-6, 839-44, 847-52 passim. PubMed ID: 10137064
[TBL] [Abstract][Full Text] [Related]
17. PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications.
Karara AH; Edeki T; McLeod J; Tonelli AP; Wagner JA
J Clin Pharmacol; 2010 Apr; 50(4):380-91. PubMed ID: 20097935
[TBL] [Abstract][Full Text] [Related]
18. How some patients in new-drug trials can get cut off.
Anand G
Wall St J (East Ed); 2003 Dec; ():A1, A11. PubMed ID: 14971381
[No Abstract] [Full Text] [Related]
19. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
20. Current trends in the clinical development of peptide therapeutics.
Saladin PM; Zhang BD; Reichert JM
IDrugs; 2009 Dec; 12(12):779-84. PubMed ID: 19943221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
